Aripiprazole is no longer viewed solely as a treatment for primary psychosis. In 2026, one of the most significant trends in the Aripiprazole Market is its rising use as an "Adjunctive Treatment" for Major Depressive Disorder (MDD). For patients who do not achieve full remission with standard antidepressants alone, adding a "Partial Dopamine Agonist" like aripiprazole can "Boost" the...